Peter W. Groeneveld
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Peter W. Groeneveld has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
Feifei Yang
Division of General Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
5 shared publicationsMary Anne Matta
Division of General Internal Medicine, Department of Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA
5 shared publicationsJanice J. Suh
Division of General Internal Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
4 shared publicationsAndrea G. Segal
Department of Veterans Affairs Center for Health Equity Research and Promotion, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
3 shared publications- Andrew J. Epstein
Department of Veterans Affairs' Center for Health Equity Research and Promotion, Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Pennsylvania
3 shared publications Judy A. Shea
Department of Veterans Affairs Center for Health Equity Research and Promotion Pittsburgh PA
3 shared publications
Latest Publications
- 26 August 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (8) , 702-713
Impact of the MISSION Act on Quality and Outcomes of Major Cardiovascular Procedures Among Veterans
Importance: The Department of Veterans Affairs (VA) Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act expanded opportunities for veterans to obtain care outside the VA. However, the impact on health care outcomes is uncertain.Objective: To measure the MISSION Act’s impact on travel times and outcomes of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and aortic valve replacement (AVR).Design, Setting, and Participants: This retrospective difference-in-differences cohort study included veterans receiving nonemergent/nonurgent PCI, CABG, or AVR between October 2016 and September 2022 in non-VA hospitals under MISSION Act coverage or in VA hospitals in the 48 contiguous US states or the District of Columbia. Analyses were conducted in 2023-2024.Exposures: Veterans eligible for non-VA care under the MISSION Act by living far from ( >60 minutes) the nearest VA medical center vs veterans living near (≤60 minutes) a VA medical center.Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as rehospitalization for cardiovascular cause or mortality within 30 days of the procedure, and travel times for care were the primary outcomes.Results: The cohort comprised veterans receiving PCI (n = 43 000; 42 066 [98%] male; mean [SD] age, 69 [8.8] years), CABG (n = 23 301; 22 197 [98%] male; mean [SD] age, 69 [7.7] years), or AVR (n = 14 682; 14 336 [98%] male; mean [SD] age, 74 [9.6] years). After MISSION implementation, mean PCI travel times increased by 1.3 minutes for near patients and decreased by 29.2 minutes for far patients (difference in differences, −30.5 minutes; P < .001). Mean CABG travel times increased by 9.4 minutes for near patients and decreased by 18.1 minutes for far patients (difference in differences, −27.4 minutes; P < .001). Mean travel times for AVR increased by 10.0 minutes for near patients and decreased by 23.0 minutes for far patients (difference in differences, −33.1 minutes; P < .001). After MISSION implementation, mean PCI MACE rates decreased by 0.5 percentage points for near patients and increased by 2.3 percentage points for far patients (difference in differences, 2.8 percentage points; P <.001). Mean CABG MACE rates decreased by 6.5 percentage points for near patients and increased by 1.6 percentage points for far patients (difference in differences, 8.1 percentage points; P < .001). AVR MACE rates were not statistically different between the groups (P = .45).Conclusions and Relevance: MISSION Act implementation was associated with substantial decreases in travel times among veterans who became geographically eligible for non-VA care. For these patients undergoing PCI or CABG, MISSION Act implementation was also associated with worsened 30-day MACE rates.
- 26 August 2025
- Published by American Medical Association (AMA) in JAMA
- Vol. 334 (8) , 702-713
Impact of the MISSION Act on Quality and Outcomes of Major Cardiovascular Procedures Among Veterans
Importance: The Department of Veterans Affairs (VA) Maintaining Internal Systems and Strengthening Integrated Outside Networks (MISSION) Act expanded opportunities for veterans to obtain care outside the VA. However, the impact on health care outcomes is uncertain.Objective: To measure the MISSION Act’s impact on travel times and outcomes of percutaneous coronary intervention (PCI), coronary artery bypass grafting (CABG), and aortic valve replacement (AVR).Design, Setting, and Participants: This retrospective difference-in-differences cohort study included veterans receiving nonemergent/nonurgent PCI, CABG, or AVR between October 2016 and September 2022 in non-VA hospitals under MISSION Act coverage or in VA hospitals in the 48 contiguous US states or the District of Columbia. Analyses were conducted in 2023-2024.Exposures: Veterans eligible for non-VA care under the MISSION Act by living far from ( >60 minutes) the nearest VA medical center vs veterans living near (≤60 minutes) a VA medical center.Main Outcomes and Measures: Major adverse cardiovascular events (MACE), defined as rehospitalization for cardiovascular cause or mortality within 30 days of the procedure, and travel times for care were the primary outcomes.Results: The cohort comprised veterans receiving PCI (n = 43 000; 42 066 [98%] male; mean [SD] age, 69 [8.8] years), CABG (n = 23 301; 22 197 [98%] male; mean [SD] age, 69 [7.7] years), or AVR (n = 14 682; 14 336 [98%] male; mean [SD] age, 74 [9.6] years). After MISSION implementation, mean PCI travel times increased by 1.3 minutes for near patients and decreased by 29.2 minutes for far patients (difference in differences, −30.5 minutes; P < .001). Mean CABG travel times increased by 9.4 minutes for near patients and decreased by 18.1 minutes for far patients (difference in differences, −27.4 minutes; P < .001). Mean travel times for AVR increased by 10.0 minutes for near patients and decreased by 23.0 minutes for far patients (difference in differences, −33.1 minutes; P < .001). After MISSION implementation, mean PCI MACE rates decreased by 0.5 percentage points for near patients and increased by 2.3 percentage points for far patients (difference in differences, 2.8 percentage points; P <.001). Mean CABG MACE rates decreased by 6.5 percentage points for near patients and increased by 1.6 percentage points for far patients (difference in differences, 8.1 percentage points; P < .001). AVR MACE rates were not statistically different between the groups (P = .45).Conclusions and Relevance: MISSION Act implementation was associated with substantial decreases in travel times among veterans who became geographically eligible for non-VA care. For these patients undergoing PCI or CABG, MISSION Act implementation was also associated with worsened 30-day MACE rates.
- Open Access
- 3 July 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (7) , e197238
Association Between Spending and Survival of Chronic Heart Failure Across Veterans Affairs Medical Centers
Chronic heart failure (CHF) is prevalent among 5% of US veterans in the Department of Veterans Affairs (VA) health care system,1 and annual mortality among those with CHF is 15%.2 The health care costs for patients with CHF are both high3 and highly variable in non-VA patient populations.4 High CHF expenditures are associated with both the high frequency of hospitalizations4 and the costs of testing, pharmacotherapy, devices, and chronic disease management programs.5 Small area variation in health care spending for the population of patients with CHF and others has been well documented,6-8 including variation in spending across the VA.9 Although comparisons of VA costs and outcomes in highly selected VA clinical populations have been previously reported,10 relatively little is known about whether and how the variation in health care spending among large patient populations with chronic disease across the VA is associated with the substantial variation in cardiovascular outcomes in these populations.1,11 In particular, it is unknown whether VA Medical Centers (VAMCs) with greater than average spending per veteran achieve better than average survival rates.
- 3 July 2019
- Published by American Medical Association (AMA) in JAMA Network Open
- Vol. 2 (7) , e197238
Open AccessAssociation Between Spending and Survival of Chronic Heart Failure Across Veterans Affairs Medical Centers
Chronic heart failure (CHF) is prevalent among 5% of US veterans in the Department of Veterans Affairs (VA) health care system,1 and annual mortality among those with CHF is 15%.2 The health care costs for patients with CHF are both high3 and highly variable in non-VA patient populations.4 High CHF expenditures are associated with both the high frequency of hospitalizations4 and the costs of testing, pharmacotherapy, devices, and chronic disease management programs.5 Small area variation in health care spending for the population of patients with CHF and others has been well documented,6-8 including variation in spending across the VA.9 Although comparisons of VA costs and outcomes in highly selected VA clinical populations have been previously reported,10 relatively little is known about whether and how the variation in health care spending among large patient populations with chronic disease across the VA is associated with the substantial variation in cardiovascular outcomes in these populations.1,11 In particular, it is unknown whether VA Medical Centers (VAMCs) with greater than average spending per veteran achieve better than average survival rates.
- Open Access
- 7 May 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (9) , e011672
Quality and Value of Health Care in the Veterans Health Administration: A Qualitative Study
Background: The attitudes of Department of Veterans Affairs ( VA ) cardiovascular clinicians toward the VA 's quality‐of‐care processes, clinical outcomes measures, and healthcare value are not well understood. Methods and Results: Semistructured telephone interviews were conducted with cardiovascular healthcare providers (n=31) at VA hospitals that were previously identified as high or low performers in terms of healthcare value. The interviews focused on VA providers’ experiences with measures of processes, outcomes, and value (ie, costs relative to outcomes) of cardiovascular care. Most providers were aware of process‐of‐care measurements, received regular feedback generated from those data, and used that feedback to change their practices. Fewer respondents reported clinical outcomes measures influencing their practice, and virtually no participants used value data to inform their practice, although several described administrative barriers limiting high‐cost care. Providers also expressed general enthusiasm for the VA 's quality measurement/improvement efforts, with relatively few criticisms about the workload or opportunity costs inherent in clinical performance data collection. There were no material differences in the responses of employees of low‐performing versus high‐performing VA medical centers. Conclusions: Regardless of their medical center's healthcare value performance, most VA cardiovascular providers used feedback from process‐of‐care data to inform their practice. However, clinical outcomes data were used more rarely, and value‐of‐care data were almost never used. The limited use of outcomes data to inform healthcare practice raises concern that healthcare outcomes may have insufficient influence, whereas the lack of value data influencing cardiovascular care practices may perpetuate inefficiencies in resource use.
- 7 May 2019
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 8 (9) , e011672
Open AccessQuality and Value of Health Care in the Veterans Health Administration: A Qualitative Study
Background: The attitudes of Department of Veterans Affairs ( VA ) cardiovascular clinicians toward the VA 's quality‐of‐care processes, clinical outcomes measures, and healthcare value are not well understood. Methods and Results: Semistructured telephone interviews were conducted with cardiovascular healthcare providers (n=31) at VA hospitals that were previously identified as high or low performers in terms of healthcare value. The interviews focused on VA providers’ experiences with measures of processes, outcomes, and value (ie, costs relative to outcomes) of cardiovascular care. Most providers were aware of process‐of‐care measurements, received regular feedback generated from those data, and used that feedback to change their practices. Fewer respondents reported clinical outcomes measures influencing their practice, and virtually no participants used value data to inform their practice, although several described administrative barriers limiting high‐cost care. Providers also expressed general enthusiasm for the VA 's quality measurement/improvement efforts, with relatively few criticisms about the workload or opportunity costs inherent in clinical performance data collection. There were no material differences in the responses of employees of low‐performing versus high‐performing VA medical centers. Conclusions: Regardless of their medical center's healthcare value performance, most VA cardiovascular providers used feedback from process‐of‐care data to inform their practice. However, clinical outcomes data were used more rarely, and value‐of‐care data were almost never used. The limited use of outcomes data to inform healthcare practice raises concern that healthcare outcomes may have insufficient influence, whereas the lack of value data influencing cardiovascular care practices may perpetuate inefficiencies in resource use.
- 1 November 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (11) , 1130-1131
Ensuring Optimal Adjustment for Determinations of Institutional Quality Reply
In Reply We thank our US Department of Veterans Affairs (VA) colleagues Valle et al for their interest in our research and for their thoughtful letter. As noted in our report,1 we agree that administrative data have inherent limitations because of unmeasured variables and variation in coding practices. Nevertheless, VA administrative data are currently used in public reporting of VA hospital outcomes,2 and validation studies confirm that administrative data—including data from the VA—remain useful for hospital-level outcomes comparisons despite their limitations.3
- 1 November 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (11) , 1130-1131
Ensuring Optimal Adjustment for Determinations of Institutional Quality Reply
In Reply We thank our US Department of Veterans Affairs (VA) colleagues Valle et al for their interest in our research and for their thoughtful letter. As noted in our report,1 we agree that administrative data have inherent limitations because of unmeasured variables and variation in coding practices. Nevertheless, VA administrative data are currently used in public reporting of VA hospital outcomes,2 and validation studies confirm that administrative data—including data from the VA—remain useful for hospital-level outcomes comparisons despite their limitations.3
- Open Access
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (7) , 563-571
Outcomes of Care for Ischemic Heart Disease and Chronic Heart Failure in the Veterans Health Administration
Importance The Department of Veterans Affairs (VA) operates a nationwide system of hospitals and hospital-affiliated clinics, providing health care to more than 2 million veterans with cardiovascular disease. While data permitting hospital comparisons of the outcomes of acute cardiovascular care (eg, myocardial infarction) are publicly available, little is known about variation across VA medical centers (VAMCs) in outcomes of care for populations of patients with chronic, high-risk cardiovascular conditions. Objective To determine whether there are substantial differences in cardiovascular outcomes across VAMCs. Design, Setting, and Participants Retrospective cohort study comprising 138 VA hospitals and each hospital’s affiliated outpatient clinics. Patients were identified who received VA inpatient or outpatient care between 2010 and 2014. Separate cohorts were constructed for patients diagnosed as having either ischemic heart disease (IHD) or chronic heart failure (CHF). The data were analyzed between June 24, 2015, and November 21, 2017. Exposures Hierarchical linear models with VAMC-level random effects were estimated to compare risk-standardized mortality rates for IHD and for CHF across 138 VAMCs. Mortality estimates were risk standardized using a wide array of patient-level covariates derived from both VA and Medicare health care encounters. Main Outcomes and Measures All-cause mortality. Results The cohorts comprised 930 079 veterans with IHD and 348 015 veterans with CHF; both cohorts had a mean age of 77 years and were predominantly white (IHD, n = 822 665 [89%] and CHF, n = 287 871 [83%]) and male (IHD, n = 916 684 [99%] and CHF n = 341 352 [98%]). The VA-wide crude annual mortality rate was 7.4% for IHD and 14.5% for CHF. For IHD, VAMCs’ risk-standardized mortality varied from 5.5% (95% CI, 5.2%-5.7%) to 9.4% (95% CI, 9.0%-9.9%) (P < .001 for the difference). For CHF, VAMCs’ risk-standardized mortality varied from 11.1% (95% CI, 10.3%-12.1%) to 18.9% (95% CI, 18.3%-19.5%) (P < .001 for the difference). Twenty-nine VAMCs had IHD mortality rates that significantly exceeded the national mean, while 35 VAMCs had CHF mortality rates that significantly exceeded the national mean. Veterans Affairs medical centers’ mortality rates among their IHD and CHF populations were not associated with 30-day mortality rates for myocardial infarction (R2 = 0.01;P = .35) and weakly associated with hospitalized heart failure 30-day mortality (R2 = 0.16;P < .001) and the VA’s star rating system (R2 = 0.06;P = .005). Conclusions and Relevance Risk-standardized mortality rates for IHD and CHF varied widely across the VA health system, and this variation was not well explained by differences in demographics or comorbidities. This variation may signal substantial differences in the quality of cardiovascular care between VAMCs.
- 1 July 2018
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (7) , 563-571
Open AccessOutcomes of Care for Ischemic Heart Disease and Chronic Heart Failure in the Veterans Health Administration
Importance The Department of Veterans Affairs (VA) operates a nationwide system of hospitals and hospital-affiliated clinics, providing health care to more than 2 million veterans with cardiovascular disease. While data permitting hospital comparisons of the outcomes of acute cardiovascular care (eg, myocardial infarction) are publicly available, little is known about variation across VA medical centers (VAMCs) in outcomes of care for populations of patients with chronic, high-risk cardiovascular conditions. Objective To determine whether there are substantial differences in cardiovascular outcomes across VAMCs. Design, Setting, and Participants Retrospective cohort study comprising 138 VA hospitals and each hospital’s affiliated outpatient clinics. Patients were identified who received VA inpatient or outpatient care between 2010 and 2014. Separate cohorts were constructed for patients diagnosed as having either ischemic heart disease (IHD) or chronic heart failure (CHF). The data were analyzed between June 24, 2015, and November 21, 2017. Exposures Hierarchical linear models with VAMC-level random effects were estimated to compare risk-standardized mortality rates for IHD and for CHF across 138 VAMCs. Mortality estimates were risk standardized using a wide array of patient-level covariates derived from both VA and Medicare health care encounters. Main Outcomes and Measures All-cause mortality. Results The cohorts comprised 930 079 veterans with IHD and 348 015 veterans with CHF; both cohorts had a mean age of 77 years and were predominantly white (IHD, n = 822 665 [89%] and CHF, n = 287 871 [83%]) and male (IHD, n = 916 684 [99%] and CHF n = 341 352 [98%]). The VA-wide crude annual mortality rate was 7.4% for IHD and 14.5% for CHF. For IHD, VAMCs’ risk-standardized mortality varied from 5.5% (95% CI, 5.2%-5.7%) to 9.4% (95% CI, 9.0%-9.9%) (P < .001 for the difference). For CHF, VAMCs’ risk-standardized mortality varied from 11.1% (95% CI, 10.3%-12.1%) to 18.9% (95% CI, 18.3%-19.5%) (P < .001 for the difference). Twenty-nine VAMCs had IHD mortality rates that significantly exceeded the national mean, while 35 VAMCs had CHF mortality rates that significantly exceeded the national mean. Veterans Affairs medical centers’ mortality rates among their IHD and CHF populations were not associated with 30-day mortality rates for myocardial infarction (R2 = 0.01;P = .35) and weakly associated with hospitalized heart failure 30-day mortality (R2 = 0.16;P < .001) and the VA’s star rating system (R2 = 0.06;P = .005). Conclusions and Relevance Risk-standardized mortality rates for IHD and CHF varied widely across the VA health system, and this variation was not well explained by differences in demographics or comorbidities. This variation may signal substantial differences in the quality of cardiovascular care between VAMCs.
- 1 December 2017
- Published by Wolters Kluwer Health in Medical Care
- Vol. 55 (12) , e131-e136
Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer
Background: Targeted therapy for patients with lung and colon cancer based on tumor molecular profiles is an important cancer treatment strategy, but the impact of gene mutation tests on cancer treatment and outcomes in large populations is not clear. In this study, we assessed the accuracy of an algorithm to identify tumor mutation testing in administrative claims data during a period before test-specific Current Procedural Terminology codes were available. Materials and Methods: We used Pennsylvania Cancer Registry data to select patients with lung or colon cancer diagnosed between 2007 and 2011 who were treated at the University of Pennsylvania Health System, and we obtained their administrative claims. A combination of Current Procedural Terminology laboratory codes (stacking codes) was used to identify potential tumor mutation testing in the claims data. Patients’ electronic medical records were then searched to determine whether tumor mutation testing actually had been performed. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Results: An algorithm using stacking codes had moderate sensitivity (86% for lung cancer and 81% for colon cancer) and high specificity (98% for lung cancer and 96% for colon cancer). Sensitivity and specificity did not vary significantly during 2007–2011. In patients with lung cancer, PPV was 98% and NPV was 92%. In patients with colon cancer, PPV was 96% and NPV was 83%. Conclusions: An algorithm using stacking codes can identify tumor mutation testing in administrative claims data among patients with lung and colon cancer with a high degree of accuracy.
- 1 December 2017
- Published by Wolters Kluwer Health in Medical Care
- Vol. 55 (12) , e131-e136
Validation of Molecular Pathology Codes for the Identification of Mutational Testing in Lung and Colon Cancer
Background: Targeted therapy for patients with lung and colon cancer based on tumor molecular profiles is an important cancer treatment strategy, but the impact of gene mutation tests on cancer treatment and outcomes in large populations is not clear. In this study, we assessed the accuracy of an algorithm to identify tumor mutation testing in administrative claims data during a period before test-specific Current Procedural Terminology codes were available. Materials and Methods: We used Pennsylvania Cancer Registry data to select patients with lung or colon cancer diagnosed between 2007 and 2011 who were treated at the University of Pennsylvania Health System, and we obtained their administrative claims. A combination of Current Procedural Terminology laboratory codes (stacking codes) was used to identify potential tumor mutation testing in the claims data. Patients’ electronic medical records were then searched to determine whether tumor mutation testing actually had been performed. The sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) were calculated. Results: An algorithm using stacking codes had moderate sensitivity (86% for lung cancer and 81% for colon cancer) and high specificity (98% for lung cancer and 96% for colon cancer). Sensitivity and specificity did not vary significantly during 2007–2011. In patients with lung cancer, PPV was 98% and NPV was 92%. In patients with colon cancer, PPV was 96% and NPV was 83%. Conclusions: An algorithm using stacking codes can identify tumor mutation testing in administrative claims data among patients with lung and colon cancer with a high degree of accuracy.
- 1 September 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 2 (5) , 421-428
Cost-Effectiveness of Therapeutic Hypothermia After Cardiac Arrest
Background— Therapeutic hypothermia can improve survival and neurological outcomes in cardiac arrest survivors, but its cost-effectiveness is uncertain. We sought to evaluate the cost-effectiveness of treating comatose cardiac arrest survivors with therapeutic hypothermia. Methods and Results— A decision model was developed to capture costs and outcomes for patients with witnessed out-of-hospital ventricular fibrillation arrest who received conventional care or therapeutic hypothermia. The Hypothermia After Cardiac Arrest (HACA) trial inclusion criteria were assumed. Model inputs were determined from published data, cooling device companies, and consultation with resuscitation experts. Sensitivity analyses and Monte Carlo simulations were performed to identify influential variables and uncertainty in cost-effectiveness estimates. The main outcome measures were quality-adjusted survival after cardiac arrest, cost of hypothermia implementation, cost of posthospital discharge care, and incremental cost-effectiveness ratios. In our model, postarrest patients receiving therapeutic hypothermia gained an average of 0.66 quality-adjusted life years compared with conventional care, at an incremental cost of $31 254. This yielded an incremental cost-effectiveness ratio of $47 168 per quality-adjusted life year. Sensitivity analyses demonstrated that poor neurological outcome postcooling and costs associated with posthypothermia care (in-hospital and long term) were the most influential variables in the model. Even at extreme estimates for costs, the cost-effectiveness of hypothermia remained less than $100 000 per quality-adjusted life year. In 91% of 10 000 Monte Carlo simulations, the incremental cost-effectiveness ratio was less than $100 000 per quality-adjusted life year. Conclusions— In cardiac arrest survivors who meet HACA criteria, therapeutic hypothermia with a cooling blanket improves clinical outcomes with cost-effectiveness that is comparable to many economically acceptable health care interventions in the United States.
- 1 September 2009
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Quality and Outcomes
- Vol. 2 (5) , 421-428
Cost-Effectiveness of Therapeutic Hypothermia After Cardiac Arrest
Background— Therapeutic hypothermia can improve survival and neurological outcomes in cardiac arrest survivors, but its cost-effectiveness is uncertain. We sought to evaluate the cost-effectiveness of treating comatose cardiac arrest survivors with therapeutic hypothermia. Methods and Results— A decision model was developed to capture costs and outcomes for patients with witnessed out-of-hospital ventricular fibrillation arrest who received conventional care or therapeutic hypothermia. The Hypothermia After Cardiac Arrest (HACA) trial inclusion criteria were assumed. Model inputs were determined from published data, cooling device companies, and consultation with resuscitation experts. Sensitivity analyses and Monte Carlo simulations were performed to identify influential variables and uncertainty in cost-effectiveness estimates. The main outcome measures were quality-adjusted survival after cardiac arrest, cost of hypothermia implementation, cost of posthospital discharge care, and incremental cost-effectiveness ratios. In our model, postarrest patients receiving therapeutic hypothermia gained an average of 0.66 quality-adjusted life years compared with conventional care, at an incremental cost of $31 254. This yielded an incremental cost-effectiveness ratio of $47 168 per quality-adjusted life year. Sensitivity analyses demonstrated that poor neurological outcome postcooling and costs associated with posthypothermia care (in-hospital and long term) were the most influential variables in the model. Even at extreme estimates for costs, the cost-effectiveness of hypothermia remained less than $100 000 per quality-adjusted life year. In 91% of 10 000 Monte Carlo simulations, the incremental cost-effectiveness ratio was less than $100 000 per quality-adjusted life year. Conclusions— In cardiac arrest survivors who meet HACA criteria, therapeutic hypothermia with a cooling blanket improves clinical outcomes with cost-effectiveness that is comparable to many economically acceptable health care interventions in the United States.
- 23 July 2009
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 50 (5) , 1040-1048
Comparative effectiveness of carotid arterial stenting versus endarterectomy
- 23 July 2009
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 50 (5) , 1040-1048
Comparative effectiveness of carotid arterial stenting versus endarterectomy
- 1 June 2008
- Published by Elsevier in American Heart Journal
- Vol. 155 (6) , 1097-1105
The costs of drug-eluting coronary stents among Medicare beneficiaries
- 1 June 2008
- Published by Elsevier in American Heart Journal
- Vol. 155 (6) , 1097-1105
The costs of drug-eluting coronary stents among Medicare beneficiaries